MX2011011879A - Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes. - Google Patents

Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.

Info

Publication number
MX2011011879A
MX2011011879A MX2011011879A MX2011011879A MX2011011879A MX 2011011879 A MX2011011879 A MX 2011011879A MX 2011011879 A MX2011011879 A MX 2011011879A MX 2011011879 A MX2011011879 A MX 2011011879A MX 2011011879 A MX2011011879 A MX 2011011879A
Authority
MX
Mexico
Prior art keywords
drug
betaxanthins
derivatives
prediabetes
diabetes
Prior art date
Application number
MX2011011879A
Other languages
Spanish (es)
Inventor
Agustin Lugo Radillo
Original Assignee
Agustin Lugo Radillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agustin Lugo Radillo filed Critical Agustin Lugo Radillo
Priority to MX2011011879A priority Critical patent/MX2011011879A/en
Priority to PCT/MX2012/000100 priority patent/WO2013058642A1/en
Publication of MX2011011879A publication Critical patent/MX2011011879A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes, which has the effect of reducing the concentration of plasma glucose following administration. This drug can contain one or more betaxanthins or any of the derivatives thereof either individually or in multiple different combinations. In addition, the drug can contain a combination of other pharmaceutical products. The drug can be administered by any route. Said drug, which contains one or more betaxanthins or any of the derivatives thereof and is intended for the treatment of prediabetes and diabetes, can be administered to any eukaryotic organism, including humans.
MX2011011879A 2011-10-17 2011-10-17 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes. MX2011011879A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2011011879A MX2011011879A (en) 2011-10-17 2011-10-17 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.
PCT/MX2012/000100 WO2013058642A1 (en) 2011-10-17 2012-10-15 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011011879A MX2011011879A (en) 2011-10-17 2011-10-17 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.

Publications (1)

Publication Number Publication Date
MX2011011879A true MX2011011879A (en) 2013-04-16

Family

ID=48141149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011879A MX2011011879A (en) 2011-10-17 2011-10-17 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.

Country Status (2)

Country Link
MX (1) MX2011011879A (en)
WO (1) WO2013058642A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109295123A (en) * 2018-09-12 2019-02-01 天津大学 A kind of biological production of betaxanthin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119872A (en) * 1996-12-19 2000-01-31 Israel State Pharmaceutical compositions containing antioxidant betalains and a method for their preparation
JP2005336069A (en) * 2004-05-25 2005-12-08 Masaki Sato Antidiabetic composition

Also Published As

Publication number Publication date
WO2013058642A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
PH12014502040A1 (en) Heterocyclyl compounds
NI201100194A (en) DERIVATIVES OF HAVE [2, 3 - B] PYRIDINE AS INHIBITORS OF VIRAL REPLICATION
WO2014108571A3 (en) Cancer drug and uses
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
HUE043540T2 (en) Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
IN2014DN09434A (en)
WO2013087716A3 (en) Fgfr antibody drug conjugates (adcs) and the use thereof
MX2014002171A (en) Combination treatments for hepatitis c.
MX357780B (en) Polycyclic derivatives, preparation method and medical uses thereof.
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
WO2012145575A3 (en) Therapy for leukemia
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
GEP20156332B (en) Pyrazoles as crth2 antagonists
IN2015DN02999A (en)
MX2011011879A (en) Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
MX2011011880A (en) Use of derivatives of betanidine and isobetanidine for the preparation of a drug for the treatment of prediabetes and diabetes.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
UA109944U (en) PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL
MX2011011881A (en) Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.
WO2012091425A3 (en) Composition containing a 4-hydroxytamoxifen analog or the pharmaceutically acceptable salts thereof as an active ingredient for preventing or treating diseases associated with metabolic syndrome
WO2013127539A3 (en) Pharmaceutical formulation containing flupirtin
WO2012145234A3 (en) Cyclopropyl derivatives and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal